Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results

Ophthalmology

Volumn 119, Issue 5, 2012, Pages 992-1000

  Larsen, Michael ^a   Schmidt Erfurth, Ursula ^b   Lanzetta, Paolo ^c   Wolf, Sebastian ^d   Simader, Christian ^b   Tokaji, Erika ^e   Pilz, Stefan ^e   Weisberger, Annemarie ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF BERN   (Switzerland)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORNEA THICKNESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; EYE PAIN; FEMALE; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR HYPEREMIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RHINOPHARYNGITIS; SHAM PROCEDURE; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84860452217     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.02.002     Document Type: Article

References (25)

1. N.M. Bressler, S.B. Bressler, S.L. Fine Age-related macular degeneration Surv Ophthalmol 32 1988 375 413
2. P.K. Kaiser Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration Curr Med Res Opin 23 2007 477 487 (Pubitemid 46463889)
3. K. Spilsbury, K.L. Garrett, W.Y. Shen Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization Am J Pathol 157 2000 135 144 (Pubitemid 30641731)
4. Verteporfin In Photodynamic Therapy Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2 Am J Ophthalmol 131 2001 541 560
5. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2 Arch Ophthalmol 119 2001 198 207
6. P.K. Kaiser Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no 8 Graefes Arch Clin Exp Ophthalmol 244 2006 1132 1142 (Pubitemid 44269592)
7. U. Schmidt-Erfurth, M. Niemeyer, W. Geitzenauer, S. Michels Time course and morphology of vascular effects associated with photodynamic therapy Ophthalmology 112 2005 2061 2069 (Pubitemid 41720981)
8. U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor Invest Ophthalmol Vis Sci 44 2003 4473 4480 (Pubitemid 37186285)
9. S.O. Gollnick, S.S. Evans, H. Baumann Role of cytokines in photodynamic therapy-induced local and systemic inflammation Br J Cancer 88 2003 1772 1779 (Pubitemid 36760423)
10. N. Ferrara, T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25 (Pubitemid 27076453)
11. N. Shams, T. Ianchulev Role of vascular endothelial growth factor in ocular angiogenesis Ophthalmol Clin North Am 19 2006 335 344 (Pubitemid 44279356)
12. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
13. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444 (Pubitemid 44511558)
14. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
15. D.S. Boyer, J.S. Heier, D.M. Brown A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
16. U. Schmidt-Erfurth, B. Eldem, R. Guymer EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study Ophthalmology 118 2011 831 839
17. F.G. Holz, W. Amoaku, J. Donate SUSTAIN Study Group Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study Ophthalmology 118 2011 663 671
18. A.E. Fung, G.A. Lalwani, P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
19. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
20. D.M. Brown, M. Michels, P.K. Kaiser ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 2009 57 65
21. U. Schmidt-Erfurth, S. Wolf PROTECT Study Group Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration Br J Ophthalmol 92 2008 1628 1635
22. U.E. Wolf-Schnurrbusch, C.K. Brinkmann, L. Berger, S. Wolf Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration Acta Ophthalmol 89 2011 585 590
23. D.S. Boyer, A.N. Antoszyk, C.C. Awh MARINA Study Group Subgroup analysis of the MARINA Study of ranibizumab in neovascular age-related macular degeneration Ophthalmology 114 2007 246 252 (Pubitemid 46172497)
24. F. Parmeggiani, C. Costagliola, D. Gemmati Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration Pharmacogenet Genomics 17 2007 1039 1046 (Pubitemid 351339488)
25. F. Parmeggiani, C. Costagliola, D. Gemmati Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration Invest Ophthalmol Vis Sci 49 2008 3100 3106